<DOC>
	<DOCNO>NCT02763995</DOCNO>
	<brief_summary>Cardiovascular disease ( CVD ) main cause death Spain . In HIV patient , uncontrolled viral replication , antiretroviral therapy ( ART ) coinfections contribute develop metabolic disease increase prevalence risk factor CVD . These patient age result high probability comorbidities , increase number medication , possibility negative outcome associate medication ( NOM ) increase cardiovascular risk ( CVR ) . Various study establish pharmaceutical care ( PC ) result well control cardiovascular risk factor . The purpose study evaluate impact pharmaceutical care achieve pharmacotherapy follow-up cardiovascular risk health relate quality life ( HRQoL ) HIV patient older 50 .</brief_summary>
	<brief_title>Pharmacotherapy Follow-up Older HIV-infected Patients</brief_title>
	<detailed_description>Quasi-experimental clinical study , pre-post intervention , perform one patient cohort . Study carry tertiary hospital . The population constitute patient receive care outpatient department pharmacy service use antiretroviral therapy . Variables obtain patient ' clinical history , dispense record interview patient . Main variable : - cardiovascular risk estimate accord Systematic Coronary Risk Evaluation ( SCORE ) Registre Gironí del Cor ( REGICOR ) equations - HRQoL measure Short-Form 36-Item Health Survey ( SF-36 ) Medical Outcomes Study HIV Health Survey ( MOS-HIV ) questionnaire . Other variable : sociodemographic , clinical , pharmacological , related CVR , related NOM intervention . Interventions perform every two month complete 12 month follow-up . Pharmacotherapy follow-up conduct accord Dader method . The intervention health education lifestyle modification , improve adherence aim resolution NOM drug-related problem .</detailed_description>
	<criteria>patient older 50 year use antiretroviral therapy cardiovascular risk ≥2 % , estimate SCORE equation accept participate research signature write informed consent patient neurodegenerative deficit HIV dementia participant clinical trial non signature write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>pharmaceutical care</keyword>
	<keyword>old patient</keyword>
	<keyword>cardiovascular risk</keyword>
	<keyword>pharmacotherapy follow</keyword>
</DOC>